<DOC>
	<DOCNO>NCT00740805</DOCNO>
	<brief_summary>This phase I trial study side effect best dose veliparib , cyclophosphamide , doxorubicin hydrochloride give together treat patient solid tumor non-Hodgkin lymphoma spread area body remove surgery . Veliparib may stop growth cancer cell block enzymes need cell growth . Drugs use chemotherapy , cyclophosphamide doxorubicin hydrochloride , work different way stop growth cancer cell , either kill cell , stop dividing , stop spread . Giving veliparib , cyclophosphamide , doxorubicin hydrochloride may kill cancer cell .</brief_summary>
	<brief_title>Veliparib , Cyclophosphamide , Doxorubicin Hydrochloride Treating Patients With Metastatic Unresectable Solid Tumors Non-Hodgkin Lymphoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Identify maximally tolerate dose ( MTD ) dose limit toxicity ( DLT ) cyclophosphamide combine escalate dos ABT-888 ( veliparib ) . II . Identify maximally tolerate dose ( MTD ) dose limit toxicity ( DLT ) cyclophosphamide doxorubicin ( doxorubicin hydrochloride ) combine escalate dos ABT-888 . SECONDARY OBJECTIVES : I . Evaluate effect ABT-888 systemic clearance parent cyclophosphamide dose normalized area curve ( AUC ) 4-hydroxy ( 4-OH ) cyclophosphamide use combination , use historical single-agent cyclophosphamide 4-OH data . II . Evaluate effect cyclophosphamide administration systemic pharmacokinetics ABT-888 primary metabolite A-925088 ( M8 ) , compare pharmacokinetic ( PK ) parameter ABT-888 day 1 ( cyclophosphamide ) day 3 ( cyclophosphamide administration ) ; PK sample analysis collect patient enrol 2/15/2012 . III . Evaluate inhibition poly ( adenosine diphosphate [ ADP ] ribose ) polymerase ( PARP ) use immunoassay design measure PAR level baseline on-study peripheral blood mononuclear cell ( PBMC ) sample ; PBMC sample PAR analysis collect patient enrol 2/15/2012 . IV . Evaluate gamma H2A histone family , member X ( H2AX ) baseline on-study circulate tumor cell sample evaluate point maximal deoxyribonucleic acid ( DNA ) damage combination cyclophosphamide doxorubicin ABT-888 . OUTLINE : This dose-escalation study veliparib cyclophosphamide . GROUP I : Patients receive veliparib orally ( PO ) every 12 hour day 1-4 cyclophosphamide intravenously ( IV ) 60 minute day 3 . GROUP II : Patients receive veliparib PO every 12 hour day 1-4 , cyclophosphamide IV 60 minute day 3 , doxorubicin hydrochloride IV 15 minute day 3 . GROUP III : Patients receive veliparib PO every 12 hour day 1-7 , cyclophosphamide IV 60 minute day 1 , doxorubicin hydrochloride IV 15 minute day 1 . GROUP IV : Patients receive veliparib PO every 12 hour day 1-14 , cyclophosphamide IV 60 minute day 1 , doxorubicin hydrochloride 15 minute day 1 . In group , course repeat every 21 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow 4 week .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Veliparib</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Patients must histologically confirm malignancy metastatic unresectable standard curative palliative measure exist longer effective ; patient either solid tumor nonHodgkin 's lymphoma eligible At recommended Phase II dose level , additional 6 12 patient group follow criterion enrol : document breast cancer ( BRCA ) 1/BRC2 mutation , triplenegative breast cancer define estrogen receptor ( ER ) negative , progesterone receptor ( PR ) negative , human epidermal growth factor receptor ( HER ) 2negative , patient would benefit cyclophosphamidebased regimen On schedule ABT888 give 7 14 day , patient metastatic breast cancer enrol Patients must &gt; = 4 week since prior chemotherapy radiation therapy ( &gt; = 6 week last regimen include carmustine [ BCNU ] mitomycin C ) ; patient previously treat cyclophosphamide necessarily exclude Patients nonHodgkin 's lymphoma amenable hematopoietic stem cell transplantation curative intent may participate stem cell transplant refuse indicated Eastern Cooperative Oncology Group ( ECOG ) performance status = &lt; 2 Life expectancy great 2 month Hemoglobin &gt; = 9.0 g/dL Absolute neutrophil count ( ANC ) &gt; = 1,500/uL Platelets &gt; = 100,000/uL Total bilirubin within normal institutional limit Aspartate aminotransferase ( AST ) ( serum glutamic oxaloacetic transaminase [ SGOT ] ) alanine aminotransferase ( ALT ) ( serum glutamate pyruvate transaminase [ SGPT ] ) = &lt; 2.5 X institutional upper limit normal ( ULN ) , = &lt; 5 x ULN know hepatic metastasis Creatinine within normal institutional limit OR creatinine clearance &gt; = 60 ml/min/1.73 m^2 patient creatinine level institutional normal Prothrombin time ( PT ) /international normalize ratio ( INR ) /partial thromboplastin time ( PTT ) = &lt; 1.2 X institutional ULN Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation ; woman become pregnant suspect pregnant participating study , inform treat physician immediately Patients enrol group treatment adriamycin cycloblastin ( AC ) : ejection fraction &gt; = 50 % multigated acquisition scan ( MUGA ) echocardiogram Patients must sign informed consent Concurrent administration investigational agent ( ) Prior highdose therapy require hematopoietic stem cell transplantation Prior anticancer treatment involve radioactive pharmaceutical History allergic reaction attribute compound similar chemical biologic composition ABT888 and/or cyclophosphamide Patients receive medication substance strong inhibitor strong inducer cytochrome P450 , family 3 , subfamily A , polypeptide 4 ( CYP 3A4 ) , cytochrome P450 , family 2 , subfamily B , polypeptide 6 ( 2B6 ) , cytochrome P450 , family 2 , subfamily C , polypeptide 9 ( 2C9 ) cytochrome P450 , family 2 , subfamily C , polypeptide 19 ( 2C19 ) prohibit ; time screening , patient currently receive list prohibited medication ( ) , medication ( ) must discontinue period le 7 day prior administration first dose study medication order patient meet study eligibility except follow substance washout 6 month : amiodarone Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement ; New York Heart Association ( NYHA ) grade II great congestive heart failure Pregnant woman exclude study ; breastfeed discontinue mother treated ABT888 ; potential risk may also apply agent use study Human immunodeficiency virus ( HIV ) positive patient combination antiretroviral therapy ineligible ; appropriate study undertake patient receive combination antiretroviral therapy indicate ; NOTE : HIV seropositive patient receive combination antiretroviral therapy cluster differentiation ( CD ) 4 cell &gt; = 350/mm^3 , opportunistic infection meet eligibility criterion may participate study Any condition ( e.g. , gastrointestinal tract disease result inability take oral medication requirement IV alimentation , prior surgical procedure affect absorption , active peptic ulcer disease ) impair ability swallow retain ABT888 capsule Patients gastrointestinal condition might predispose drug intolerability poor drug absorption ( e.g. , inability take oral medication requirement IV alimentation , prior surgical procedure affect absorption , malabsorption syndrome , active peptic ulcer disease ) exclude ; subject ulcerative colitis , inflammatory bowel disease , partial complete small bowel obstruction also exclude Patients active central nervous system ( CNS ) metastases excluded Patients CNS metastasis treat must steroid treatment &gt; 3 month , asymptomatic steroid treatment prior study enrollment Patients symptoms suggest CNS metastases brain magnetic resonance imaging ( MRI ) within 28 day enrollment confirm absence CNS metastases ; contrast compute tomography ( CT ) acceptable patient unable undergo brain MRI Patients active seizure history active seizure Any medical , social , psychological condition may significantly affect safety and/or compliance Patients enrol group treatment AC : prior doxorubicin exposure &gt; 300 mg/m^2 equivalent anthracycline exposure ( i.e. , epirubicin dose &gt; 540 mg/m^2 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>